Unique ID issued by UMIN | UMIN000019698 |
---|---|
Receipt number | R000022755 |
Scientific Title | Phase III study of Efficacy and Safety of SJP-0118 in bacterial blepharitis, dacryocystitis or hordeolum/ acute suppurative chalazion. |
Date of disclosure of the study information | 2015/11/09 |
Last modified on | 2016/07/28 09:17:17 |
Phase III study of Efficacy and Safety of SJP-0118 in bacterial blepharitis, dacryocystitis or hordeolum/ acute suppurative chalazion.
Clinical study of SJP-0118 in extraocular bacterial infections.
Phase III study of Efficacy and Safety of SJP-0118 in bacterial blepharitis, dacryocystitis or hordeolum/ acute suppurative chalazion.
Clinical study of SJP-0118 in extraocular bacterial infections.
Japan |
acterial blepharitis, dacryocystitis or hordeolum/ acute suppurative chalazion
Ophthalmology |
Others
NO
This study aimed to determine the efficacy and safety of SJP-0118 in the treatment of bacterial extraocular infections.
Safety,Efficacy
Clinical resolution will be assessed at day 3, 7 and 14 according to Guidelines for the Clinical Trials of Antibacterial Ophthalmic Solution [Nippon Ganka Gakkai Zasshi. 2015;119(4)273-86].
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
SJP-0118 is instilled by twice on the first two days (once in the morning and at bedtime) and once a day in the morning for the following 12 days.
19 | years-old | <= |
Not applicable |
Male and Female
1) Signature of the subject or legally authorized representative on the Informed Consent Form.
2) Male or female subject who is at least 19 year of age.
3) Subjects must have had a clinical diagnosis of bacterial blepharitis, dacryocystitis or hordeolum/ acute suppurative chalazion.
1) Subjects with suspected fungal, viral, or Acanthamoeba infection.
2) Subjects with suspected allergic conjunctivitis.
3) History of recurrent corneal erosion syndrome.
4) Any corneal epithelial loss, specifically any corneal ulcer (except for superficial punctate keratitis).
5) Subject with best-corrected visual acuity equal to or less than 0.2 in both eyes.
6) Subject need to use concomitant therapy during the study.
7) Use of any antibiotic (systemic, topical or dermally around eyelid) within 1 week of enrollment.
8) Use of any corticosteroid or nonsteroidal antiinflammatory drug (systemic of topical).
9) Ocular surgery within the past 90 days.
10) Any cancer, clinically significant hepatic, renal, cardiovascular or endocrine system disorders.
11) Known hypersensitivity or adverse effect to azithromycin, any macrolide antibiotic, or to any of the ingredients in the study medications.
12) Willing to use contact lens or punctual plug during the study.
13) Pregnant, nursing, possibility of pregnancy or hope for the pregnancy during the study.
14) Participation in any other clinical study.
15) History of use azithromycin eye drops.
45
1st name | |
Middle name | |
Last name | Yoshitsugu Inoue |
Tottori University
Division of Ophthalmology and Visual Science, Faculty of Medicine
86 Nishi-cho,Yonago-shi,Tottori-ken, Japan
0859-33-1111
yoinoue@grape.med.tottori-u.ac.jp
1st name | |
Middle name | |
Last name | Yoshikuni Nakamura |
Senju Pharmaceutical co.,ltd.
Regulatory Affairs & Medical Writing, Clinical Development
2-5-8, Hirano-machi, Chuo-ku, Osaka, Japan
06-6201-9605
y-nakamura@senju.co.jp
Senju Pharmaceutical co.,ltd.
Senju Pharmaceutical co.,ltd.
Profit organization
NO
2015 | Year | 11 | Month | 09 | Day |
Unpublished
Completed
2015 | Year | 08 | Month | 17 | Day |
2015 | Year | 10 | Month | 01 | Day |
2015 | Year | 11 | Month | 09 | Day |
2016 | Year | 07 | Month | 28 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022755